<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: <z:chebi fb="0" ids="2038">Azacitidine</z:chebi> and <z:chebi fb="0" ids="50131">decitabine</z:chebi> are used to treat patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) in the United States (US) </plain></SENT>
<SENT sid="1" pm="."><plain>This study sought to assess their relative cost-effectiveness </plain></SENT>
<SENT sid="2" pm="."><plain>DESIGN AND METHODS: The authors developed a cost-effectiveness Markov model (1-month cycles) tracking hypothetical cohorts of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients treated with <z:chebi fb="0" ids="2038">azacitidine</z:chebi> or <z:chebi fb="0" ids="50131">decitabine</z:chebi> over 2 years </plain></SENT>
<SENT sid="3" pm="."><plain>The model used a US payer perspective and 2009 costs </plain></SENT>
<SENT sid="4" pm="."><plain>Health states modeled included <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> with Transfusion Dependence, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> with Transfusion Independence, Progression to <z:hpo ids='HP_0004808'>Acute Myelogenous Leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), and <z:hpo ids='HP_0011420'>Death</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Incremental cost-effectiveness outcomes included cost per quality-adjusted life year (QALY), cost per life year (LY), cost per patient-month of transfusion independence, and cost per case of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> progression avoided </plain></SENT>
<SENT sid="6" pm="."><plain>One-way sensitivity analyses were performed on key model parameters </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: Compared to <z:chebi fb="0" ids="50131">decitabine</z:chebi>, <z:chebi fb="0" ids="2038">azacitidine</z:chebi> was associated with better survival (1.512 LYs vs 1.292), more QALYs gained (1.041 vs 0.870), more patient-months with transfusion independence (8.328 vs 6.224), and a greater proportion of patients avoiding progression to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (50.9% vs 28.5%) </plain></SENT>
<SENT sid="8" pm="."><plain>Total per-patient costs over 2 years for <z:chebi fb="0" ids="2038">azacitidine</z:chebi> were lower than for <z:chebi fb="0" ids="50131">decitabine</z:chebi> ($150,322 vs $166, 212) </plain></SENT>
<SENT sid="9" pm="."><plain>LIMITATIONS: To inform and update the model over time, it will be important that randomized or observational clinical studies be conducted to directly compare <z:chebi fb="0" ids="2038">azacitidine</z:chebi> and <z:chebi fb="0" ids="50131">decitabine</z:chebi>, provide new information on how these medicines are used, and on their relative clinical effectiveness </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: Results demonstrate that <z:chebi fb="0" ids="2038">azacitidine</z:chebi> provides greater clinical benefit and costs less than <z:chebi fb="0" ids="50131">decitabine</z:chebi> across <z:hpo ids='HP_0000001'>all</z:hpo> key outcomes </plain></SENT>
<SENT sid="11" pm="."><plain>These results accentuate the positive role of <z:chebi fb="0" ids="2038">azacitidine</z:chebi> in providing cost-effective care for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>